Statements (53)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:antibiotic
cephalosporin |
| gptkbp:approvedBy |
1979
|
| gptkbp:ATCCode |
J01DC04
|
| gptkbp:bioavailability |
95%
|
| gptkbp:brand |
gptkb:Ceclor
gptkb:Distaclor gptkb:Keflor |
| gptkbp:CASNumber |
53994-73-3
|
| gptkbp:chemicalFormula |
C15H14ClN3O4S
beta-lactam ring |
| gptkbp:contraindication |
hypersensitivity to cephalosporins
|
| gptkbp:discoveredIn |
1970s
|
| gptkbp:drugClass |
second-generation cephalosporin
|
| gptkbp:eliminationHalfLife |
0.6–0.9 hours
|
| gptkbp:excretion |
renal
|
| gptkbp:form |
gptkb:tablet
capsule oral suspension |
| https://www.w3.org/2000/01/rdf-schema#label |
Cefaclor
|
| gptkbp:indication |
tonsillitis
urinary tract infections otitis media respiratory tract infections pharyngitis skin and soft tissue infections |
| gptkbp:legalStatus |
prescription only
|
| gptkbp:mechanismOfAction |
inhibits bacterial cell wall synthesis
|
| gptkbp:metabolism |
minimal
|
| gptkbp:molecularWeight |
367.81 g/mol
|
| gptkbp:origin |
synthetic
|
| gptkbp:pregnancyCategory |
B1 (Australia)
B (US FDA) |
| gptkbp:prescribes |
adults
children elderly |
| gptkbp:proteinBinding |
23.5%
|
| gptkbp:riskFactor |
cross-reactivity with penicillin allergy
|
| gptkbp:routeOfAdministration |
oral
|
| gptkbp:sideEffect |
nausea
vomiting diarrhea abdominal pain rash allergic reactions serum sickness-like reaction |
| gptkbp:spectrumOfActivity |
Gram-positive bacteria
some Gram-negative bacteria |
| gptkbp:usedFor |
bacterial infections
|
| gptkbp:WHOModelListOfEssentialMedicines |
not included
|
| gptkbp:bfsParent |
gptkb:D01841
gptkb:D00544 |
| gptkbp:bfsLayer |
7
|